PEGylated Biopharmaceuticals
Inge A. Ivens(Bayer (United States)), Jennifer Sims, Maggie Dempster(GlaxoSmithKline (United States)), Theodora W. Salcedo(Janssen (United States)), B. O. Depelchin(UCB Pharma (Belgium)), Joy Cavagnaro(Access to Wholistic and Productive Living Institute), Laura Dill-Morton(Novartis (United States)), Peter L. Turecek(University of Vienna), William E. Achanzar(Bristol-Myers Squibb (Germany)), Andreas Baumann(Bayer (Germany)), Annamaria Brändli-Baiocco(Roche (Switzerland)), Laurie Tsuruda(BioMarin (United States)), Becky Schweighardt(BioMarin (United States)), Joan H. Lane(Biogen (United States)), Birgit M. Reipert(IMC University of Applied Sciences Krems), Armando R. Irizarry Rovira(Eli Lilly (United States))
Cited by 160
Related Papers
PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs
|Journal of Pharmaceutical Sciences|2016|707
Effects of cadmium on DNA-(Cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation
|Experimental Cell Research|2003|450
High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension
|Thrombosis and Haemostasis|2003|258
A nematode gene required for sperm vesicle fusion
|Journal of Cell Science|1997|184